Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Publication year range
1.
J Innate Immun ; 14(4): 366-379, 2022.
Article in English | MEDLINE | ID: mdl-35780770

ABSTRACT

As a serious and elusive syndrome caused by infection, sepsis causes a high rate of mortality around the world. Our investigation aims at exploring the role and possible mechanism of specificity protein-1 (SP1) in the development of sepsis. A mouse model of sepsis was established by cecal ligation perforation, and a cellular model was stimulated by lipopolysaccharide (LPS), followed by determination of the SP1 expression. It was determined that SP1 was poorly expressed in the intestinal tissues of septic mice and LPS-treated cells. Next, we examined the interactions among SP1, histone deacetylase 4 (HDAC4), and high mobility group box 1 (HMGB1) and found that SP1 bound to the HDAC4 promoter to upregulate its expression, thereby promoting the deacetylation of HMGB1. Meanwhile, gain- or loss-of-function approaches were applied to evaluate the intestinal barrier dysfunction, oxidative stress, and inflammatory response. Overexpression of SP1 or underexpression of HMGB1 was observed to reduce intestinal barrier dysfunction, oxidative stress, and inflammatory injury. Collectively, these experimental data provide evidence reporting that SP1 could promote the HDAC4-mediated HMGB1 deacetylation to reduce intestinal barrier dysfunction, oxidative stress, and inflammatory response induced by sepsis, providing a novel therapeutic target for sepsis prevention and treatment.


Subject(s)
Gastrointestinal Diseases , HMGB1 Protein/genetics , Histone Deacetylases/genetics , Sepsis , Sp1 Transcription Factor/metabolism , Animals , HMGB1 Protein/metabolism , Histone Deacetylases/metabolism , Histone Deacetylases/therapeutic use , Human Umbilical Vein Endothelial Cells/metabolism , Humans , Lipopolysaccharides/metabolism , Mice , Mice, Inbred C57BL , Oxidative Stress , Sepsis/drug therapy
2.
Mol Med ; 28(1): 9, 2022 01 28.
Article in English | MEDLINE | ID: mdl-35090386

ABSTRACT

BACKGROUND: Sepsis is a troublesome syndrome that can cause intestinal injury and even high mortality rates. Omega-3 fatty acids (FAs) are known to protect against intestinal damage. Accordingly, the current study set out to explore if omega-3 FAs could affect sepsis-induced intestinal injury with the involvement of the microRNA (miR)-1-3p/Notch3-Smad axis. METHODS: First, cecal ligation and perforation (CLP) was performed to establish septic mouse models in C57BL/6J mice, and mouse intestinal epithelial MODE-K cells were induced by lipopolysaccharide (LPS) to establish sepsis cell models. The CLP-induced septic mice or LPS-exposed cells were subjected to treatment with Omega-3 FAs and activin (Smad signaling activator), miR-1-3p inhibitor and over-expressed/short hairpin RNA (oe-/sh)-Notch3 to explore their roles in inflammation, intestinal oxidative stress and cell apoptosis. A dual-luciferase reporter gene assay was further performed to verify the regulatory relationship between miR-1-3p and Notch3. RESULTS: Omega-3 FAs inhibited CLP-induced intestinal injury and ameliorated LPS-induced intestinal epithelial cell injury by down-regulating miR-1-3p, as evidenced by decreased levels of tumor necrosis factor-α, interleukin-1ß (IL-1ß) and IL-6, in addition to diminished levels of reactive oxygen species, malondialdehyde levels and superoxide dismutase activity. Furthermore, miR-1-3p could down-regulate Notch3, which inactivated the Smad pathway. CONCLUSION: Collectively, our findings indicated that omega-3 FAs elevate the expression of Notch3 by down-regulating miR-1-3p, and then blocking the Smad pathway to alleviate intestinal epithelial inflammation and oxidative stress injury caused by sepsis.


Subject(s)
Fatty Acids, Omega-3/metabolism , Gene Expression Regulation , Intestinal Diseases/etiology , Intestinal Diseases/metabolism , MicroRNAs/genetics , Receptor, Notch3/genetics , Sepsis/complications , Animals , Biomarkers , Disease Management , Disease Models, Animal , Disease Susceptibility , Gene Expression Profiling , Intestinal Diseases/diagnosis , Intestinal Diseases/therapy , Intestinal Mucosa/metabolism , Intestinal Mucosa/pathology , Mice , Models, Biological , Oxidative Stress , Receptor, Notch3/metabolism , Sepsis/etiology , Signal Transduction , Smad Proteins
3.
Oncol Lett ; 8(3): 1195-1201, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25120686

ABSTRACT

The B7 family consists of activating and inhibitory molecules that regulate immune responses. Recent research demonstrated the roles of soluble B7-H3 (sB7-H3) and soluble B7-H1 (sB7-H1) in the blood serum of various tumors; however, none of these studies investigated the expression of these proteins in the cerebral spinal fluid (CSF) and blood serum of patients with glioma. The aim of the present study was to investigate the expression of B7-H3 and B7-H1 in the CSF, blood serum and tissues of patients with glioma and their correlation with clinicopathological data. Between January 2012 and November 2012, samples were obtained from 78 patients with glioma, four CSF samples were obtained from patients with a moderate traumatic brain injury, four brain tissue samples were obtained from patients with a traumatic brain injury and 40 blood serum samples were obtained from healthy individuals. The expression of B7-H3 and B7-H1 in the CSF, blood serum and tumor samples of the patients with high-grade glioma was found to be higher than that in the patients with low-grade glioma. However, no significant differences in sB7-H3 and sB7-H1 expression were observed in the blood serum of the patients with glioma compared with the healthy control subjects. In addition, the expression of sB7-H3 and sB7-H1 in the CSF of the patients with glioma was higher than that in the CSF of the patients with a moderate traumatic brain injury. Furthermore, in the patients with glioma, B7-H3 and B7-H1 expression in the CSF and tumor tissue, although not in the blood serum, correlated with the glioma grade.

4.
J Neurooncol ; 116(2): 251-9, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24276989

ABSTRACT

Forkhead box protein 3 (Foxp3) is known as a specific marker for regulatory T cells which contribute to immunosuppression in tumor microenvironment. However, existing studies regarding clinical significance of Foxp3+ tumor-infiltrating lymphocytes (TILs) in glioblastoma (GBM) remained discrepant. In this study, we aimed to explore whether this subtype of TILs correlated with prognosis in patients with GBM. Foxp3+ TILs as well as CD8+ ones were detected by immunohistochemistry on paraffin-embedded tumor samples from 62 patients. Staining for p53, MGMT and Ki-67 were also performed. The correlation of TIL subtypes with clinicopathologic features were analyzed. Progression-free survival (PFS) and overall survival (OS) were estimated by Kaplan-Meier method and compared using log-rank test. Independent prognostic factors for PFS and OS were determined through univariate and multivariate analysis. Significant correlation was found between Foxp3 and CD8 expression (P = 0.003), but not between TIL subtypes and clinicopathologic characteristics. Patients with higher density of Foxp3+ TILs showed relatively shorter PFS (P < 0.001) and OS (P = 0.003) whereas patients with higher density of CD8+ TILs obtained no significant differences in survival. Survival analysis based on molecular classifications further clarified these predictive values. Univariate and multivariate analysis revealed that frequency of Foxp3+ TILs was probably associated with both PFS (P = 0.002) and OS (P = 0.003). In conclusion, the results suggest that Foxp3 positive infiltrates could provide an independent predictive factor in GBM.


Subject(s)
Brain Neoplasms/diagnosis , Forkhead Transcription Factors/metabolism , Glioblastoma/diagnosis , Lymphocytes, Tumor-Infiltrating/metabolism , Lymphocytes, Tumor-Infiltrating/pathology , Adolescent , Adult , Aged , Brain Neoplasms/radiotherapy , CD8 Antigens/metabolism , DNA Modification Methylases/metabolism , DNA Repair Enzymes/metabolism , Female , Glioblastoma/radiotherapy , Humans , Ki-67 Antigen/metabolism , Male , Middle Aged , Multivariate Analysis , Prognosis , Retrospective Studies , Tumor Suppressor Protein p53/metabolism , Tumor Suppressor Proteins/metabolism , Young Adult
5.
Chin Med J (Engl) ; 126(9): 1720-5, 2013.
Article in English | MEDLINE | ID: mdl-23652057

ABSTRACT

BACKGROUND: Angiogenesis is a prerequisite for tumor growth and plays an important role in rapidly growing tumors, such as malignant gliomas. A variety of factors controlling the angiogenic balance have been described, and among these, the endogenous inhibitor of angiogenesis, tumstatin, has drawn considerable attention. The current study investigated whether expression of tumstatin by glioma cells could alter this balance and prevent tumor formation. METHODS: We engineered stable transfectants from human glioma cell line U251 to constitutively secrete a human tumstatin protein with c-myc and polyhistidine tags. Production and secretion of the tumstatin-c-myc-His fusion protein by tumstatin-transfected cells were confirmed by Western blotting analysis. In the present study, we identify the anti-angiogenic capacity of tumstatin using several in vitro and in vivo assays. Student's t-test and one-way analysis of variance (ANOVA) test were used to determine the statistical significance in this study. RESULTS: The tumstatin transfectants and control transfectants (stably transfected with a control plasmid) had similar in vitro growth rates compared to their parental cell lines. However, the conditioned medium from the tumstatin transfected tumor cells significantly inhibits proliferation and causes apoptosis of endothelial cells. It also inhibits tube formation of endothelial cells on Matrigel. Examination of armpit tumors arising from cells overexpressing tumstatin repress the growth of tumor, accompanying the decreased density of CD31 positive vessels in tumors ((5.62 ± 1.32)/HP), compared to the control-transfectants group ((23.84 + 1.71)/HP) and wild type U251 glioma cells group ((29.33 + 4.45)/HP). CONCLUSION: Anti-angiogenic gene therapy using human tumstatin gene may be an effective strategy for the treatment of glioma.


Subject(s)
Autoantigens/genetics , Brain Neoplasms/therapy , Cell Proliferation , Collagen Type IV/genetics , Genetic Therapy , Glioma/therapy , Neovascularization, Pathologic/prevention & control , Animals , Brain Neoplasms/blood supply , Cell Line, Tumor , Glioma/blood supply , Glioma/pathology , Humans , Mice , Mice, Inbred BALB C , Platelet Endothelial Cell Adhesion Molecule-1/analysis , Transfection
6.
Chin J Cancer ; 32(12): 653-60, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23327799

ABSTRACT

Previous studies indicated that B7-H4, the youngest B7 family, negatively regulates T cell-mediated immunity and is significantly overexpressed in many human tumors. Tumor stem cells are purported to play a role in tumor renewal and resistance to radiation and chemotherapy. However, the link between B7-H4 and tumor stem cells is unclear. In this study, we investigated B7-H4 expression in the medium of human glioma U251 cell cultures. Immunofluorescence results showed that U251 cells cultured in serum-free medium (supplemented with 2% B27, 20 ng/mL epidermal growth factor, 20 ng/mL basic fibroblast growth factor) maintained stem-like cell characteristics, including expression of stem cell marker CD133 and the neural progenitor cell markers nestin and SOX2. In contrast, U251 cells cultured in serum-containing medium highly expressed differentiation marker glial fibrillary acidic protein. Flow cytometry analysis showed serum-free medium-cultured U251 cells expressed higher intracellular B7-H4 than serum-containing medium-cultured U251 cells (24%-35% vs. 8%-11%, P < 0.001). Immunofluorescence in purified monocytes from normal human peripheral blood mononuclear cells revealed moderate expression of B7-H4 after stimulation with conditioned medium from U251 cells cultured in serum-containing medium. Moreover, conditioned medium from U251 stem-like cells had a significant stimulation effect on B7-H4 expression compared with serum-containing conditioned medium (P < 0.01). Negative costimulatory molecule B7-H4 was preferentially expressed in U251 stem-like cells, and conditioned medium from these cells more effectively induced monocytes to express B7-H4 than conditioned medium from U251 cells cultured in the presence of serum. Our results show that U251 stem-like cells may play a more crucial role in tumor immunoloregulation with high expression of B7-H4.


Subject(s)
Brain Neoplasms/metabolism , Glioma/metabolism , Monocytes/metabolism , Neoplastic Stem Cells/metabolism , V-Set Domain-Containing T-Cell Activation Inhibitor 1/metabolism , AC133 Antigen , Antigens, CD/metabolism , Brain Neoplasms/pathology , Cell Line, Tumor , Cells, Cultured , Culture Media, Conditioned , Culture Media, Serum-Free , Gene Expression Regulation, Neoplastic , Glial Fibrillary Acidic Protein/metabolism , Glioma/pathology , Glycoproteins/metabolism , Humans , Monocytes/cytology , Neoplastic Stem Cells/pathology , Nestin/metabolism , Peptides/metabolism , SOXB1 Transcription Factors/metabolism
7.
Transfus Med ; 20(1): 66-9, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19725902

ABSTRACT

HDN attributed to the rare Rh variants has become more and more significant caused by anti-D, but the compatible blood is usually very difficult to obtain when exchange transfusion is required. We treated a 10-hour neonate of O, D + C + c - E - e+ blood group with severe HDN due to anti-Rh17 with least incompatible blood typed O, D + C - c + E + e-. The neonatal hemolysis was relieved obviously and bilirubin was reduced gradually after exchange transfusion. The infant was discharged in good health 13 days after birth with 135.0 g/L, 28.0 micromol/L and 10.7 micromol/L of Hb, total bilirubin and direct bilirubin, respectively. No sequelae were observed in a three-year follow-up. The result suggesting that the least incompatible blood is an alternative choice for exchange transfusion in severe HDN due to anti-Rh17 in case that Rh17 antigen-negative blood is unavailable.


Subject(s)
Blood Component Transfusion/methods , Blood Group Incompatibility/immunology , Blood Grouping and Crossmatching , Hydrops Fetalis/therapy , Isoantibodies/immunology , Rh-Hr Blood-Group System/immunology , Adult , Blood Group Incompatibility/drug therapy , Erythrocyte Transfusion , Female , Humans , Hydrops Fetalis/immunology , Hyperbilirubinemia, Neonatal/etiology , Hyperbilirubinemia, Neonatal/radiotherapy , Hyperbilirubinemia, Neonatal/therapy , Immunoglobulins, Intravenous/therapeutic use , Immunosuppressive Agents/therapeutic use , Infant, Newborn , Leukocyte Reduction Procedures , Male , Methylprednisolone/therapeutic use , Plasma , Pregnancy , Rh Isoimmunization , Rho(D) Immune Globulin , Ultraviolet Therapy , Young Adult
8.
Zhongguo Dang Dai Er Ke Za Zhi ; 11(1): 41-3, 2009 Jan.
Article in Chinese | MEDLINE | ID: mdl-19149921

ABSTRACT

OBJECTIVE: Multilocular brain abscess in children is a serious neurosurgical emergency and remains a serious, life-threatening disease. This study evaluated the role of neuroendoscopy in treating multilocular brain abscess in children. METHODS: Between January 2002 and June 2007, 16 children with multilocular brain abscess underwent an operation using a pure endoscopic procedure. RESULTS: Increased intracranial pressure was relieved after operation in the 16 patients. CT/MRI after operation showed the abscess cavities disappeared and only the residual abscess walls existed in the 16 patients. Fourteen patients were followed up for 6 months to 5 years after surgery. Abscess walls disappeared in 13 patients and abscess recurred only in 1 patient. CONCLUSIONS: Neuroendoscopy for treatment of multilocular brain abscess is safe and effective in children.


Subject(s)
Brain Abscess/surgery , Neuroendoscopy/methods , Adolescent , Anti-Bacterial Agents/therapeutic use , Child , Child, Preschool , Female , Humans , Infant , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...